Stason Pharmaceuticals

Established in 1989, Stason Industrial Corporation entered the US generics market with the formation of Stason Pharmaceuticals, Inc. in 1994. While venturing into NDA development, we continue to develop these products through our global network of affiliates, partners and distributors. In 2008, we launched our Brand Division when we obtained exclusive commercialization rights to novel proprietary compounds in the area of oncology.

As an established organization in the industry, it is a unique place to work and build a career. Since opening in 1994, we have been a building-ground for several of our current & past employees, in their pursuit to build their careers in the industry-we would like to continue being a part of this growth.

Stason Industrial Corporation entered the U.S. generics market with the establishment of Stason Pharmaceuticals in 1994, and currently holds a portfolio of approved ANDAs. Our portfolio offers generic pharmaceutical products, marketed through our global partners. These generic drugs are initially filed under an Abbreviated New Drug Application (ANDA) in the US or Abbreviated New Drug Submission (ANDS) in Canada.

In 2008, we launched our Brand Division when acquiring exclusive development & commercialization rights to, two early-phase, novel, proprietary compounds in the area of oncology. This division is focused on New Chemical Entities (NCEs), which provide for unmet medical needs. We're dedicated to building our branded portfolio through internal development; as well as, licensing & acquisition.

Through our off-shore affiliates, Stason offers API synthesis that includes custom manufacturing of organic molecules from milligram to kilogram quantities. Stason also develops new processes for the synthesis of target molecules, including biotransformation processes for the preparation of chiral molecules.